Absorption of clonazepam after intranasal and buccal administration

Department of Clinical Pharmacy and Toxicology, Maasland Hospital, Sittard, The Netherlands.
British Journal of Clinical Pharmacology (Impact Factor: 3.88). 05/1995; 39(4):449-51. DOI: 10.1111/j.1365-2125.1995.tb04476.x
Source: PubMed


Serum concentrations of clonazepam after intranasal, buccal and intravenous administration were compared in a cross-over study in seven healthy male volunteers. Each subject received a 1.0 mg dose of clonazepam intranasally and buccally and 0.5 mg intravenously. A Cmax of 6.3 +/- 1.0 ng ml-1 (mean; +/- s.d.) was measured 17.5 min (median) (range 15-20 min) after intranasal administration. A second peak (4.6 +/- 1.3 ng ml-1) caused by oral absorption was seen after 1.7 h (range 0.7-3.0 h). After buccal administration a Cmax of 6.0 +/- 3.0 ng ml-1 was measured after 50 min (range 30-90 min) with a second peak of 6.5 +/- 2.5 ng ml-1 after 3.0 h (range 2.0-4.0 h). Two minutes after i.v. injection of 0.5 mg clonazepam the serum concentration was 27 +/- 18 ng ml-1. It is concluded that intranasal clonazepam is an alternative to buccal administration. However, the Cmax of clonazepam after intranasal administration is not high enough to recommend the intranasal route as an alternative to intravenous injection.

Download full-text


Available from: Rob Janknegt,

Click to see the full-text of:

Article: Absorption of clonazepam after intranasal and buccal administration

0 B

See full-text
  • Source
    • "However, caregivers in The Netherlands are not qualified to administer parenteral medication, so this alternative is not feasible in the residential setting. Buccal clonazepam (Schols-Hendriks et al., 1995) and midazolam (Schwagmeier et al., 1998; Scott et al., 1999; Body & Ijaz, 2005; McIntyre et al., 2005) are effective as out-of-hospital treatment for seizure exacerbations, but hypersalivation, jerking movements of the jaw, or general restlessness may preclude the buccal route. Nasal lorazepam (Ahmad et al., 2006) and midazolam nasal drip (Kendall et al., 1997; Fisgin et al., 2000; Scheepers et al., 2000; Smith & Carley, 2005) have been proven effective in this situation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Rectal diazepam is established as a standard rescue or emergency treatment for seizure or status epilepticus; however, the rectal route of administration has not been universally accepted. To determine if an alternative route of administration of a benzodiazepine was equally effective, we compared a novel midazolam HCl concentrated nasal spray (MDZ-n) with diazepam rectal solution (DZP-r) in the treatment of prolonged seizures in a residential epilepsy center. In 21 adult patients with medically refractory epilepsy, 124 seizure-exacerbations were treated by their caregivers, alternatively with 10 mg DZP-r and 10 mg concentrated MDZ-n, two or three treatments with each medication for each patient. No difference was demonstrated in efficacy or time to effect between the two drugs. Common treatment emerging adverse effects were drowsiness for both drugs in more than 50% of the administrations, and short-lasting local irritation after 29% of MDZ-n. No severe adverse events occurred. The nasal spray was preferred to the rectal solution by 16 of 21 caregivers and patients conjointly. MDZ-n was equal to DZP-r with respect to efficacy and side effects in the suppression of seizure exacerbations. The majority of patients and caregivers preferred the nasal spray over the rectal formulation.
    Epilepsia 10/2009; 51(3):478-82. DOI:10.1111/j.1528-1167.2009.02333.x · 4.57 Impact Factor

  • Pharmaceutical Development and Technology 08/1997; 2(3):293-6. DOI:10.3109/10837459709031449 · 1.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Focus has been on the nasal mucosa as an alternative route to achieve faster and higher drug absorption. The whole process of determining the feasibility of a drug candidate for nasal delivery begins with appropriate and adequate preformulation studies leading to the development of potential nasal products which are stable, safe and effective. The effects of physicochemical properties, biological factors, and other factors on systemic nasal drug delivery are discussed.
    Advanced drug delivery reviews 02/1998; 29(1-2):89-116. DOI:10.1016/S0169-409X(97)00063-X · 15.04 Impact Factor
Show more